TAT delivery of a PTEN peptide inhibitor has direct cardioprotective effects and improves outcomes in rodent models of cardiac arrest-Reference-Cited by-同舟云学术

TAT delivery of a PTEN peptide inhibitor has direct cardioprotective effects and improves outcomes in rodent models of cardiac arrest

Published:2021-05-01 Issue:5 Volume:320 Page:H2034-H2043
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

Zhu Xiangdong¹^ORCID,Li Jing¹,Wang Huashan¹,Gasior Filip M.,Lee Chunpei²,Lin Shaoxia¹,Zhu Zhiyi¹,Wang Youhua¹,Justice Cody N.¹²^ORCID,O'Donnell J. Michael²,Vanden Hoek Terry L.

Affiliation:

1. Program in Advanced Resuscitation Medicine, Department of Emergency Medicine, Center for Cardiovascular Research, University of Illinois Hospital & Health Sciences System, Chicago, Illinois;

2. Department of Physiology and Biophysics, Center for Cardiovascular Research, University of Illinois Hospital & Health Sciences System, Chicago, Illinois

Abstract

We have designed a cell-permeable peptide, TAT-PTEN9c, to improve cardiac arrest survival. It blocked endogenous PTEN binding to its adaptor and enhanced Akt signaling in mouse cardiomyocytes. It improved mouse survival after cardiac arrest, which is related to improved glucose metabolism and reduced glucose shunting to sorbitol in critical organs.

Funder

Chicago Biomedical Consortium

HHS | NIH | National Heart, Lung, and Blood Institute

HHS | NIH | National Institute of General Medical Sciences

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00513.2020

Reference34 articles.

1. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway